Provides RNAi-based high-throughput screening and analysis featuring
Dharmacon technologies and expertise
WALTHAM, Mass., June 19 /PRNewswire-FirstCall/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO), the world leader in serving science, has
opened a new RNAi Discovery and Therapeutic Services laboratory at its RNAi
research and production center in Lafayette, Colorado, USA. The new
laboratory offers advanced RNAi (RNA-interference) screening and analysis
services, as well as development of new therapeutic technologies involving
RNAi.
"We have an industry-leading position in RNA- and RNAi-based
technologies through our Dharmacon product line, now marketed under the
Thermo Scientific brand," said Marc N. Casper, executive vice president of
Thermo Fisher Scientific. "Our core expertise in RNAi biology and
therapeutic technology development, high-throughput screening, RNA
chemistry and drug discovery research, combined with our unique portfolio
of bioreagents, instrument systems and robotics, enables us to perform
highly advanced contract services in-house. We can also offer customers the
option of transferring this integrated workflow to their own facilities."
The RNAi Discovery and Therapeutic Services laboratory features a
highly integrated platform of Thermo Scientific technologies, including
Dharmacon siRNA and miRNA libraries, BioImage and Cellomics high-content
screening reagents and image analysis instrumentation, as well as robotics
and software for laboratory automation.
"By providing RNAi-based screening on a contract basis, we will make it
possible for any laboratory to realize the benefits of this important
advancement in drug discovery," added Casper. "The RNAi Discovery and
Therapeutic Services laboratory provides clients with access to unmatched
scientific expertise and the ability to rapidly achieve meaningful results
from this innovative workflow, while providing training and systems
recommendations to clients establishing their own internal capabilities."
The RNAi contract services support researchers in pharmaceutical,
biotechnology and academic fields by providing critical drug-discovery
activities including target identification, target validation, biomarker
discovery and RNAi therapeutic technology development. The laboratory will
also provide supplemental resources and expertise for overburdened labs
already using RNAi technology. Services range from a single screen to
multi- component projects, and include RNAi-based high-throughput screening
and hit validation, high-content screening, microRNA expression profiling
and analysis, as well as lab automation and integration. Therapeutic
discovery and technology development is also available for clients pursuing
RNAi-based therapeutics.
For more information, please contact
Dharmacon.rnai_services@thermofisher.com or visit
http://www.thermo.com/dharmacon.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in
serving science, enabling our customers to make the world healthier,
cleaner and safer. With an annual revenue rate of more than $9 billion, we
employ 30,000 people and serve over 350,000 customers within pharmaceutical
and biotech companies, hospitals and clinical diagnostic labs,
universities, research institutions and government agencies, as well as
environmental and industrial process control settings. Serving customers
through two premier brands, Thermo Scientific and Fisher Scientific, we
help solve analytical challenges from routine testing to complex research
and discovery. Thermo Scientific offers customers a complete range of
high-end analytical instruments as well as laboratory equipment, software,
services, consumables and reagents to enable integrated laboratory workflow
solutions. Fisher Scientific provides a complete portfolio of laboratory
equipment, chemicals, supplies and services used in healthcare, scientific
research, safety and education. Together, we offer the most convenient
purchasing options to customers and continuously advance our technologies
to accelerate the pace of scientific discovery, enhance value for customers
and fuel growth for shareholders and employees alike. Visit
http://www.thermofisher.com.
The following constitutes a "Safe Harbor" statement under the Private
Securities Litigation Reform Act of 1995: This press release contains
forward- looking statements that involve a number of risks and
uncertainties. Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements are set
forth in the company's most recent Quarterly Report on Form 10-Q under the
caption "Risk Factors," which is on file with the Securities and Exchange
Commission and available in the "Investors" section of our Website under
the heading "SEC Filings." We also may make forward-looking statements
about the benefits of the merger of Thermo Electron and Fisher Scientific,
including statements about future financial and operating results, the new
company's plans, objectives, expectations and intentions and other
statements that are not historical facts. Important factors that could
cause actual results to differ materially from those indicated by
forward-looking statements include risks and uncertainties relating to: the
risk that the businesses will not be integrated successfully; the risk that
the cost savings and any other synergies from the transaction may not be
fully realized or may take longer to realize than expected; disruption from
the transaction making it more difficult to maintain relationships with
customers, employees or suppliers; competition and its effect on pricing,
spending, third-party relationships and revenues; the need to develop new
products and adapt to significant technological change; implementation of
strategies for improving internal growth; use and protection of
intellectual property; dependence on customers' capital spending policies
and government funding policies; realization of potential future savings
from new productivity initiatives; general worldwide economic conditions
and related uncertainties; the effect of changes in governmental
regulations; the effect of exchange rate fluctuations on international
operations; the effect of laws and regulations governing government
contracts; the effect of competing with certain of our customers and
suppliers; and the effect of rapid changes in the healthcare industry.
While we may elect to update forward- looking statements at some point in
the future, we specifically disclaim any obligation to do so, even if our
estimates change and, therefore, you should not rely on these
forward-looking statements as representing our views as of any date
subsequent to today.
Media Contact Information:
Lori Gorski
Phone: 781-622-1242
Email: lori.gorski@thermofisher.com
Website: http://www.thermofisher.com
Investor Contact Information
Ken Apicerno
Phone: 781-622-1111
Email: ken.apicerno@thermofisher.com
SOURCE Thermo Fisher Scientific Inc.
 back to top
Related links:
http://www.thermofisher.com
http://www.thermo.com/dharmacon/
http://www.prnewswire.com/comp/877850.html/
CONTACT:
Media, Lori Gorski, +1-781-622-1242,
lori.gorski@thermofisher.com, or Investors, Ken Apicerno,
+1-781-622-1111, ken.apicerno@thermofisher.com, both of Thermo
Fisher Scientific Inc.
|
